Recursion Pharmaceuticals Inc (RXRX)
Healthcare
Biotechnology
3.20 $
+6.0%
vs. previous close
Closing price · As of: 3. Aug 2026
Recursion Pharmaceuticals Inc (RXRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -372 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -57 | -45 | -159 | -84 | -288 | -359 | -372 | |
| 2.5 | 3.9 | 8.4 | 12 | 24 | 36 | 84 | |
| 1.4 | 4.3 | 15 | 28 | 54 | 82 | 111 | |
| 1.4 | 6.8 | 20 | 39 | – | – | – | |
| 0.4 | 31 | -0.3 | 105 | -44 | -38 | 14 | |
| 3.9 | 6.7 | 40 | 37 | 12 | 14 | 6.5 | |
| -3.9 | -8.7 | -272 | 193 | -10 | 260 | -17 | |
| – | – | 471 | – | – | – | – | |
| 0.7 | 6.3 | -13 | -0.1 | -0.8 | -4.4 | -8.4 | |
| 120 | 246 | 459 | 154 | 140 | 304 | 522 | |
| 59 | 192 | 28 | 264 | -158 | 202 | 151 | |
| -61 | -52 | -198 | -121 | -300 | -373 | -378 |
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.